With Injectable Claims, the root problem in the submission process is that payers cannot read NDC numbers on CMS 1500 forms, and there is no process in place to require providers to include such a data element.
With Injectable Claims, the root problem in the submission process is that payers cannot read NDC numbers on CMS 1500 forms, and there is no process in place to require providers to include such a data element. Remember, this is only true on claims submitted to a medical benefit, since pharmacy-adjudicated claims use NDC codes, not J codes.
There are three major ways that payers are attempting to improve the claims-payment process for injectable claims submitted to the medical benefit:
While each approach appears to be relatively straightforward, they all have associated benefits and challenges.
Risks associated with such an approach include loss of drug coverage for those members with a pharmacy carve-out and incomplete implementation of such a management initiative as a result of the large volume of provider-administrated injectables.
Some payers have required providers who submit injectable claims on a CMS 1500 to include an NDC number as well. This requires major education of the provider panel, a compliance measurement and correction processes, and IT infrastructure capable of reading and analyzing such information. There is significant variability in the compliance of such a program by geographical region and provider specialty type. We have found that oncologists commonly include NDC codes on their claims, whereas urologists and other specialists almost never do. Typically, this is a strategy used by payers who have exceptional provider service capabilities, a strong relationship with their provider panel, and who serve members in a relatively small service area.
Finally, payers are investigating the use of repricing tools, or are exploring the possibility of partnering with a vendor who provides such a service. There are a multitude of challenges associated with this approach.
From a development standpoint, the cost for a health plan to build such a tool may be as much as $1 million, and other IT projects compete heavily with this. Also, payers are still required to place NDC numbers onto each submitted claim, such that the internal or external tool can perform a comparison and submission correction.
Finally, the benefit management becomes very challenging, because as claims are changed with respect to their amount of reimbursement, different amounts are subtracted from the member's deductibles, and such "accumulators" must be carefully adjusted in parallel.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More